Stocks
Novo Nordisk (NVO) EBITDA US GAAP (year values) |
|||||||||
| 2022 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA | ? | 76 802 000 000 | 82 040 000 000 | 112 940 000 000 | 147 938 000 000 | 156 729 000 000 | 158 379 000 000 | ||
| Changes by years, y/y, % | +14% | +7% | +38% | +31% | +6% | +21.1% | |||
Novo Nordisk. EBITDA US GAAP
Novo Nordisk. EBITDA US GAAP, changes, %
Novo Nordisk. EBITDA US GAAP, sum by quarters
Novo Nordisk (NVO) EBITDA US GAAP (quarter values) |
||||||||
| 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | LTM ? | |||
| EBITDA | ? | 45 848 000 000 | 46 046 000 000 | 43 596 000 000 | 31 439 000 000 | 37 298 000 000 | 158 379 000 000 | |
| Changes by years, y/y, % | +61% | +30% | +27% | -19% | ||||
| Changes by quarters, q/q, % | +0% | -5% | -28% | +19% | ||||
